Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Exclusions
Mortality
ICU
Hospitalization
Serious outcomes
Cases
Sufficiency
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 zinc studies
00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]death1/14113/377CT​2Improvement, RR [CI]TreatmentControlThomas (RCT)12%0.88 [0.67-1.17]recov. time58 (n)50 (n)CT​2Asimi97%0.03 [0.00-0.44]ventilation0/2709/86CT​2Tau​2 = 2.06; I​2 = 74.1%Early treatment75%0.25 [0.04-1.71]1/46922/51375% improvementCarlucci38%0.62 [0.46-0.84]death/HPC54/411119/521Improvement, RR [CI]TreatmentControlKrishnan18%0.82 [0.62-1.09]death31/5861/94Yao34%0.66 [0.41-1.07]death73/19621/46Frontera (PSM)37%0.63 [0.44-0.91]death121/1,006424/2,467CT​2Abd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​2Mulhem46%0.54 [0.43-0.68]death256/1,596260/1,623Gadhiya-41%1.41 [0.69-2.57]death21/5434/229Al Sulaiman (PSM)35%0.65 [0.41-1.01]death35/13045/129Elavarasi65%0.35 [0.24-0.56]death486 (n)1,201 (n)Tau​2 = 0.05; I​2 = 69.0%Late treatment35%0.65 [0.54-0.79]598/4,043972/6,41535% improvementLouca1%0.99 [0.93-1.06]casesImprovement, RR [CI]TreatmentControlIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​2Bagheri60%0.40 [0.04-3.53]progression33 (n)477 (n)Tau​2 = 14.53; I​2 = 95.1%PrEP95%0.05 [0.00-3.97]0/436,953/21,32695% improvementSeet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP50%0.50 [0.34-0.75]33/63464/61950% improvementYasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Vogel-González77%0.23 [0.10-0.51]death9/19112/58Tomasa-Irriguible49%0.51 [0.19-1.02]ventilation7/3149/89Gonçalves82%0.18 [0.08-0.36]severe case7/55145/214Fromonot89%0.11 [0.02-0.48]hosp.6/1107/42Laing79%0.21 [0.06-0.74]death3/497/24Tau​2 = 0.15; I​2 = 36.2%Sufficiency79%0.21 [0.13-0.35]33/476231/46379% improvementAll studies51%0.49 [0.38-0.62]665/5,6658,242/29,33651% improvement24 zinc COVID-19 studiesc19zinc.com Sep 28, 20211 OT: comparison with other treatment2 CT: study uses combined treatmentTau​2 = 0.21; I​2 = 88.7%; Z = 5.80Effect extraction pre-specifiedFavors zincFavors control 00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]death1/14113/377CT​2Improvement, RR [CI]TreatmentControlThomas (RCT)12%0.88 [0.67-1.17]recov. time58 (n)50 (n)CT​2Tau​2 = 0.51; I​2 = 48.6%Early treatment39%0.61 [0.18-2.10]1/19913/42739% improvementCarlucci38%0.62 [0.46-0.84]death/HPC54/411119/521Improvement, RR [CI]TreatmentControlYao34%0.66 [0.41-1.07]death73/19621/46Frontera (PSM)37%0.63 [0.44-0.91]death121/1,006424/2,467CT​2Abd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​2Al Sulaiman (PSM)35%0.65 [0.41-1.01]death35/13045/129Elavarasi65%0.35 [0.24-0.56]death486 (n)1,201 (n)Tau​2 = 0.02; I​2 = 37.8%Late treatment41%0.59 [0.49-0.70]290/2,335617/4,46941% improvementLouca1%0.99 [0.93-1.06]casesImprovement, RR [CI]TreatmentControlBagheri60%0.40 [0.04-3.53]progression33 (n)477 (n)Tau​2 = 0.00; I​2 = 0.0%PrEP1%0.99 [0.92-1.06]0/330/4771% improvementSeet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP50%0.50 [0.34-0.75]33/63464/61950% improvementYasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Vogel-González77%0.23 [0.10-0.51]death9/19112/58Tomasa-Irriguible49%0.51 [0.19-1.02]ventilation7/3149/89Gonçalves82%0.18 [0.08-0.36]severe case7/55145/214Fromonot89%0.11 [0.02-0.48]hosp.6/1107/42Laing79%0.21 [0.06-0.74]death3/497/24Tau​2 = 0.15; I​2 = 36.2%Sufficiency79%0.21 [0.13-0.35]33/476231/46379% improvementAll studies52%0.48 [0.37-0.62]357/3,677925/6,45552% improvement19 zinc COVID-19 studies after exclusionsc19zinc.com Sep 28, 20211 OT: comparison with other treatment2 CT: study uses combined treatmentTau​2 = 0.19; I​2 = 85.9%; Z = 5.50Effect extraction pre-specifiedFavors zincFavors control 00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]1/14113/377CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.03-1.47]1/14113/37779% improvementKrishnan18%0.82 [0.62-1.09]31/5861/94Improvement, RR [CI]TreatmentControlYao34%0.66 [0.41-1.07]73/19621/46Frontera (PSM)37%0.63 [0.44-0.91]121/1,006424/2,467CT​1Abd-Elsalam (RCT)1%0.99 [0.30-3.31]5/965/95Mulhem46%0.54 [0.43-0.68]256/1,596260/1,623Gadhiya-41%1.41 [0.69-2.57]21/5434/229Al Sulaiman (PSM)35%0.65 [0.41-1.01]35/13045/129Elavarasi65%0.35 [0.24-0.56]486 (n)1,201 (n)Tau​2 = 0.07; I​2 = 75.9%Late treatment34%0.66 [0.53-0.83]542/3,622850/5,88434% improvementJothimani90%0.10 [0.01-1.76]0/205/27Improvement, RR [CI]TreatmentControlVogel-González77%0.23 [0.10-0.51]9/19112/58Laing79%0.21 [0.06-0.74]3/497/24Tau​2 = 0.00; I​2 = 0.0%Sufficiency79%0.21 [0.11-0.41]12/26024/10979% improvementAll studies41%0.59 [0.47-0.75]555/4,023887/6,37041% improvement12 zinc COVID-19 mortality resultsc19zinc.com Sep 28, 20211 CT: study uses combined treatmentTau​2 = 0.09; I​2 = 72.5%; Z = 4.43Favors zincFavors control 00.250.50.7511.251.51.752+Carlucci23%0.77 [0.53-1.10]38/41182/521Improvement, RR [CI]TreatmentControlDarban (RCT)6%0.94 [0.84-1.06]10 (n)10 (n)CT​1Tau​2 = 0.00; I​2 = 11.1%Late treatment9%0.91 [0.79-1.05]38/42182/5319% improvementJothimani92%0.08 [0.00-1.26]0/207/27Improvement, RR [CI]TreatmentControlVogel-González71%0.29 [0.20-0.41]34/19136/58Tomasa-Irriguible52%0.48 [0.20-0.91]9/3155/89Tau​2 = 0.07; I​2 = 38.4%Sufficiency66%0.34 [0.21-0.55]43/24298/17466% improvementAll studies47%0.53 [0.30-0.94]81/663180/70547% improvement5 zinc COVID-19 ICU resultsc19zinc.com Sep 28, 20211 CT: study uses combined treatmentTau​2 = 0.32; I​2 = 90.8%; Z = 2.15Favors zincFavors control 00.250.50.7511.251.51.752+Derwand82%0.18 [0.07-0.54]hosp.4/14158/377CT​1Improvement, RR [CI]TreatmentControlAsimi99%0.01 [0.00-0.16]hosp.0/27024/86CT​1Tau​2 = 3.11; I​2 = 73.1%Early treatment94%0.06 [0.00-0.95]4/41182/46394% improvementAbd-Elsalam (RCT)4%0.96 [0.86-1.08]hosp. time96 (n)95 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment4%0.96 [0.86-1.08]0/960/954% improvementIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​1Improvement, RR [CI]TreatmentControlBagheri41%0.59 [0.14-1.61]hosp.4/33167/477Tau​2 = 33.19; I​2 = 96.9%PrEP99%0.01 [0.00-34.6]4/437,120/21,32699% improvementFromonot89%0.11 [0.02-0.48]hosp.6/1107/42Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Sufficiency89%0.11 [0.02-0.48]6/1107/4289% improvementAll studies91%0.09 [0.02-0.39]14/6607,209/21,92691% improvement6 zinc COVID-19 hospitalization resultsc19zinc.com Sep 28, 20211 CT: study uses combined treatmentTau​2 = 2.88; I​2 = 93.6%; Z = 3.21Favors zincFavors control 00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]death1/14113/377CT​2Improvement, RR [CI]TreatmentControlAsimi97%0.03 [0.00-0.44]ventilation0/2709/86CT​2Tau​2 = 0.55; I​2 = 25.8%Early treatment91%0.09 [0.01-0.67]1/41122/46391% improvementCarlucci38%0.62 [0.46-0.84]death/HPC54/411119/521Improvement, RR [CI]TreatmentControlKrishnan18%0.82 [0.62-1.09]death31/5861/94Yao34%0.66 [0.41-1.07]death73/19621/46Frontera (PSM)37%0.63 [0.44-0.91]death121/1,006424/2,467CT​2Abd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​2Mulhem46%0.54 [0.43-0.68]death256/1,596260/1,623Gadhiya-41%1.41 [0.69-2.57]death21/5434/229Al Sulaiman (PSM)35%0.65 [0.41-1.01]death35/13045/129Elavarasi65%0.35 [0.24-0.56]death486 (n)1,201 (n)Tau​2 = 0.05; I​2 = 69.0%Late treatment35%0.65 [0.54-0.79]598/4,043972/6,41535% improvementIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​2Improvement, RR [CI]TreatmentControlBagheri60%0.40 [0.04-3.53]progression33 (n)477 (n)Tau​2 = 29.47; I​2 = 95.0%PrEP99%0.01 [0.00-18.2]0/436,953/21,32699% improvementSeet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP50%0.50 [0.34-0.75]33/63464/61950% improvementYasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Vogel-González77%0.23 [0.10-0.51]death9/19112/58Tomasa-Irriguible49%0.51 [0.19-1.02]ventilation7/3149/89Gonçalves82%0.18 [0.08-0.36]severe case7/55145/214Fromonot89%0.11 [0.02-0.48]hosp.6/1107/42Laing79%0.21 [0.06-0.74]death3/497/24Tau​2 = 0.15; I​2 = 36.2%Sufficiency79%0.21 [0.13-0.35]33/476231/46379% improvementAll studies56%0.44 [0.34-0.57]665/5,6078,242/29,28656% improvement22 zinc COVID-19 serious outcomesc19zinc.com Sep 28, 20211 OT: comparison with other treatment2 CT: study uses combined treatmentTau​2 = 0.20; I​2 = 80.4%; Z = 6.23Effect extraction pre-specifiedFavors zincFavors control 00.250.50.7511.251.51.752+Louca1%0.99 [0.93-1.06]Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP1%0.99 [0.93-1.06]1% improvementSeet (CLUS. RCT)27%0.73 [0.41-1.05]300/634433/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP27%0.73 [0.41-1.05]300/634433/61927% improvementFromonot28%0.72 [0.61-0.87]110/18842/52Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Sufficiency28%0.72 [0.61-0.87]110/18842/5228% improvementAll studies19%0.81 [0.64-1.03]410/822475/67119% improvement3 zinc COVID-19 case resultsc19zinc.com Sep 28, 20211 OT: comparison with other treatmentTau​2 = 0.04; I​2 = 93.3%; Z = 1.74Favors zincFavors control 00.250.50.7511.251.51.752+Yasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Vogel-González77%0.23 [0.10-0.51]death9/19112/58Tomasa-Irriguible49%0.51 [0.19-1.02]ventilation7/3149/89Gonçalves82%0.18 [0.08-0.36]severe case7/55145/214Fromonot89%0.11 [0.02-0.48]hosp.6/1107/42Laing79%0.21 [0.06-0.74]death3/497/24All studies79%0.21 [0.13-0.35]33/476231/46379% improvement7 zinc COVID-19 sufficiency studiesc19zinc.com Sep 28, 2021Tau​2 = 0.15; I​2 = 36.2%; Z = 6.21Effect extraction pre-specifiedFavors zincFavors control 00.250.50.7511.251.51.752+Thomas (RCT)12%0.88 [0.67-1.17]recov. time58 (n)50 (n)CT​2Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment12%0.88 [0.67-1.17]0/580/5012% improvementAbd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Improvement, RR [CI]TreatmentControlDarban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​2Tau​2 = 0.00; I​2 = 0.0%Late treatment15%0.85 [0.33-2.22]7/1068/10515% improvementSeet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP50%0.50 [0.34-0.75]33/63464/61950% improvementAll studies29%0.71 [0.49-1.04]40/79872/77429% improvement4 zinc COVID-19 Randomized Controlled Trialsc19zinc.com Sep 28, 20211 OT: comparison with other treatment2 CT: study uses combined treatmentTau​2 = 0.06; I​2 = 42.2%; Z = 1.76Effect extraction pre-specifiedFavors zincFavors control 00.250.50.7511.251.51.752+Abd-Elsalam (RCT)1%0.99 [0.30-3.31]5/965/95Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment1%0.99 [0.30-3.31]5/965/951% improvementAll studies1%0.99 [0.30-3.31]5/965/951% improvement1 zinc COVID-19 RCT mortality resultc19zinc.com Sep 28, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.02Favors zincFavors control 00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]death1/14113/377CT​2Improvement, RR [CI]TreatmentControlThomas (RCT)12%0.88 [0.67-1.17]recov. time58 (n)50 (n)CT​2Tau​2 = 0.51; I​2 = 48.6%Early treatment39%0.61 [0.18-2.10]1/19913/42739% improvementCarlucci38%0.62 [0.46-0.84]death/HPC54/411119/521Improvement, RR [CI]TreatmentControlKrishnan18%0.82 [0.62-1.09]death31/5861/94Yao34%0.66 [0.41-1.07]death73/19621/46Abd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​2Mulhem46%0.54 [0.43-0.68]death256/1,596260/1,623Gadhiya-41%1.41 [0.69-2.57]death21/5434/229Tau​2 = 0.07; I​2 = 68.8%Late treatment26%0.74 [0.57-0.95]442/2,421503/2,61826% improvementLouca1%0.99 [0.93-1.06]casesImprovement, RR [CI]TreatmentControlIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​2Bagheri60%0.40 [0.04-3.53]progression33 (n)477 (n)Tau​2 = 14.53; I​2 = 95.1%PrEP95%0.05 [0.00-3.97]0/436,953/21,32695% improvementSeet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP50%0.50 [0.34-0.75]33/63464/61950% improvementYasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Vogel-González77%0.23 [0.10-0.51]death9/19112/58Tomasa-Irriguible49%0.51 [0.19-1.02]ventilation7/3149/89Gonçalves82%0.18 [0.08-0.36]severe case7/55145/214Fromonot89%0.11 [0.02-0.48]hosp.6/1107/42Laing79%0.21 [0.06-0.74]death3/497/24Tau​2 = 0.15; I​2 = 36.2%Sufficiency79%0.21 [0.13-0.35]33/476231/46379% improvementAll studies52%0.48 [0.37-0.64]509/3,7737,764/25,45352% improvement20 zinc COVID-19 peer reviewed trialsc19zinc.com Sep 28, 20211 OT: comparison with other treatment2 CT: study uses combined treatmentTau​2 = 0.23; I​2 = 88.7%; Z = 5.06Effect extraction pre-specifiedFavors zincFavors control 00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]death1/14113/377CT​2Improvement, RR [CI]TreatmentControlDerwand82%0.18 [0.07-0.54]hosp.4/14158/377CT​2Thomas (RCT)12%0.88 [0.67-1.17]recov. time58 (n)50 (n)CT​2Asimi97%0.03 [0.00-0.44]ventilation0/2709/86CT​2Asimi99%0.01 [0.00-0.16]hosp.0/27024/86CT​2Asimi100%0.00 [0.00-0.08]severe case0/27051/86CT​2Carlucci38%0.62 [0.46-0.84]death/HPC54/411119/521Carlucci18%0.82 [0.54-1.25]ventilation29/41162/521Carlucci23%0.77 [0.53-1.10]ICU38/41182/521Krishnan18%0.82 [0.62-1.09]death31/5861/94Yao34%0.66 [0.41-1.07]death73/19621/46Frontera (PSM)37%0.63 [0.44-0.91]death121/1,006424/2,467CT​2Frontera (PSM)24%0.76 [0.60-0.96]death121/1,006424/2,467CT​2Abd-Elsalam (RCT)